Healthcare
Chinese GPs back AstraZeneca spin-out
A consortium led by Boyu Capital, 6 Dimensions Capital and Hillhouse Capital will invest up to $250 million in Viela Bio, a pharmaceutical research and development company being spun out from AstraZeneca.
Abraaj founder steps back as part of governance review
Arif Naqvi, founder of The Abraaj Group, has stepped back from the fund management business as part of changes to the firm’s governance and operating model. This comes after LPs expressed concerns that a healthcare fund had been misused.
Australia’s Foundry invests in Welleco
The Foundry, a private equity firm launched by executives from vitamin producer Swisse Wellness, has acquired a 25% stake in Welleco, a dietary supplement maker co-founded by supermodel Elle Macpherson (pictured).
Yunfeng, MicroPort agree international medical devices carve-out
Chinese PE firm Yunfeng Capital and Hong Kong-listed medical device manufacturer MicroPort Scientific Corporation will acquire US-listed LivaNova's cardiac rhythm management (CRM) business for $190 million in cash.
VC-backed Taiwan drug maker files for US IPO
Taiwan Liposome, a venture capital-backed manufacturer of pain medication and treatments for eye conditions, has filed for a NASDAQ IPO.
CITIC Capital-backed Harbin Pharma buys 40% stake in GNC
China’s Harbin Pharmaceutical Group, which is controlled by CITIC Capital, has agreed to acquire a 40% stake in GNC Holdings for $300 million, becoming the largest shareholder in the US-based nutritional supplements retailer.
India's HealthifyMe gets $12m Series B
Sistema Asia Fund, a VC unit of Russian conglomerate Sistema, has led a $12 million Series B funding round for Indian fitness lifestyle app operator HealthifyMe.
Vivo leads $55m round for China’s Innocare
Sino-US healthcare specialist Vivo Capital has led a $55 million round of funding for Beijing Innocare, a biopharmaceutical company that develops treatments for cancer and autoimmune diseases.
Allergan to acquire Australia's VC-backed Elastagen
Allergan, a US-listed pharmaceutical company and the owner of Botox cosmetic injectable products, has agreed to acquire Elastagen, an Australian skin treatment developer backed by a number of VCs, in a deal worth up to $260 million.
Sailing invests $30.6m in China-US biopharma player
Sailing Capital has invested $30.6 million in Cellular Biomedicine Group (CBMG), a China and US-based biopharmaceutical company focused on immunotherapy cancer treatments.
PEP to buy Australia's LifeHealthcare
Pacific Equity Partners (PEP) has agreed to buy listed Australian medical devices manufacturer LifeHealthcare for an enterprise valuation of approximately A$211 million ($166 million).
China’s Ping An raises $2.2b for healthcare, fintech units
Ping An Insurance Group has raised $2.2 billion in private equity funding for its three technology businesses: Ping An Good Doctor, Ping An Healthcare Management, and OneConnect Financial Technology.
Asia VCs invest $10m in US-Singapore biotech player
A group of VCs led by China’s 6 Dimensions Capital and Sino-US investor Danhua Capital (DHVC) has committed $10 million to US and Singapore-based Engine Biosciences.
Deal focus: Permira takes the I-Med baton from EQT
Permira's first Australia investment provides EQT Partners with an exit from medical imaging service I-Med Radiology Network
Ping An healthcare app files for Hong Kong IPO
Ping An Healthcare & Technology - the PE-backed business that runs the healthcare-focused mobile app known as Ping An Good Doctor in China - is seeking a separate listing in Hong Kong from its parent company Ping An Insurance.
Permira to buy Australia's I-Med from EQT
Permira is set to make its first investment in Australia after reaching an agreement with EQT Partners to acquire I-Med Radiology Network.
Quadria Capital backs Malaysian medical diagnostics provider
Healthcare-focused private equity firm Quadria Capital has made an investment of undisclosed size in Malaysian diagnostics services company Lablink.
Crescent buys Australian CRO business
Crescent Capital Partners has acquired Australia-based clinical research organization (CRO) Nucleus Network from The Baker Institute, an independent research institute that focuses on heart disease and diabetes.
Partners Group exits Australia cancer clinic
Partners Group has sold its entire 21% stake in Australia’s Victorian Comprehensive Cancer Centre (VCCC) to AMP Capital.
CITIC Capital takes majority control of Harbin Pharmaceutical
CITIC Capital has increased its stake in Harbin Pharmaceutical Group to 60.86%, becoming the controlling shareholder of the Chinese state-backed business in which it has been an investor since 2005.
MSPEA backs Indian medical devices, health foods businesses
Morgan Stanley Private Equity Asia (MSPEA) has completed two investments in India, committing INR1.6 billion ($25.1 million) to medical devices business Sahajanand Medical Technologies (SMT) and INR1.52 billion to health foods producer Southern Health...
CDH backs Chinese healthcare AI business
CDH Investments has invested in Huiyi Huiying (HY), a Beijing-based start-up that offers artificial intelligence-based (AI) medical imaging diagnosis. Financial terms were not disclosed.
Advantech, SDIC lead $76m round for China biotech player
Advantech Capital and SDIC Fund Management have led a $76 million Series A round for Chinese biotechnology company KBP Biosciences.
VCs invest $32m in China's HaploX Biotechnology
A group of investors including SBCVC and Kexin Capital have backed a $32 million funding round for China’s HaploX Biotechnology.